These 2 ‘Strong Buy’ Stocks Could Double From Here

Two months ago, Morgan Stanley had posed a question: ‘Will the September market swoon take longer than average to recover?’ According to the firm’s chief US equity strategist Mike Wilson, we can “Fast forward to today, and the answer to that question is a definitive…

no. Instead, our data show retail investors remain steadfast in their commitment to buying equities…”

Wilson sees retail investors giving a large boost to the market’s current upward impetus, and paradoxically, he believes that the prospect of difficult times is motivating them. In Wilson’s view, retail investors are moving into stocks as a defensive measure, recognizing that in the current economic environment of rising inflation and low interest rates, high-performance stocks provide a degree of protection for investment portfolios.

With this in mind, we wanted to take a closer look at two stocks that just received Morgan Stanley’s stamp of approval, with the firm projecting upside potential of more than 100% for each. Using TipRanks’ database, we found out that the rest of the Street is also on board as both have earned a “Strong Buy” consensus rating.

Taysha Gene Therapies (TSHA)

We’ll start with a Texas-based biopharmaceutical company, Taysha Gene Therapies. This company is focused on developing new treatments for monogenic central nervous system (CNS) diseases. The company has an active pipeline, featuring 26 adeno-associated virus therapies. These viruses are native to humans and other primates, and are used to deliver therapeutic agents – modified genes – directly to affected cells in the patient’s body. Three of Taysha’s pipeline candidates are in clinical trials, while the remainder are in pre-clinical phases of development.

Of the drug candidates in clinical trials, the leader is TSHA-120. Earlier this year, the company released visual acuity data from the Phase 1/2 trials of TSHA-120 for GAN (giant axonal neuropathy, a genetic CNS disorder that manifests in early childhood). The company is expecting to receive regulatory guidance prior to additional testing before the end of this year.

Also entering the Phase 1/2 stage of clinical trials is TSHA-101, which the company announced in September of this year had received orphan drug designation from the European Commission. TSHA-101 is a treatment for infantile GM2 gangliosidosis, another CNS disease of early childhood – but one that leads to an early death, by the age of 4.

In another recent update, the company’s Angelman Syndrome (AS) program was the subject of a recent published data. The company publicized positive proof-of-concept preclinical data supporting its approach to treatment of AS, a CNS disorder that can cause severe physical and mental disabilities starting in early childhood. The company is targeting UBE3A gene replacement therapy as a treatment for this disorder. Taysha is expected to start IND-enabling studies early next year, prior to human clinical trials.

Taysha’s active pipeline drew Morgan Stanley’s’ Matthew Harrison attention. The analyst believes “Taysha’s clinically validated gene therapy approach and a rapidly advancing, robust pipeline with multiple catalysts ahead, sets the stage for upside.”

How much upside? Harrison rates TSHA an Overweight (i.e. Buy), and his $39 price target implies a robust 140% one-year upside potential for the shares. (To watch Harrison’s track record, click here)

“We are Overweight Taysha and believe its broad AAV9 gene therapy platform, supported by management expertise in the space, has the potential to benefit patients with genetic disorders characterized by high unmet need… Taysha’s pipeline includes four late-stage assets (in GAN, GM2, CLN1, and Rett syndrome) each having a risk-adjusted peak sales potential of $1B+,” Harrison opined.

The Morgan Stanley view is no outlier on this highly speculative biotech. The stock has 8 reviews on record and all are positive, for a unanimous Strong Buy consensus rating. The shares are priced at $16.25 and their $44.14 average price target suggests room for ~172% upside growth. (See TSHA stock analysis on TipRanks)

AlloVir (ALVR)

The second Morgan Stanley pick we’ll look at is another biotech. AlloVir is focused on the treatment of viral disease, through the development of off-the-shelf, allogenic, virus-specific T-cell (VST) therapies. VSTs offer the potential to treat deadly viral diseases in patients with compromised immune systems. The company’s research pipeline features…


Continue reading at YAHOO! FINANCE


Leave a Reply

Your email address will not be published.